HORIZON-PFT: Pivotal Fracture Trial

Completed · Phase 3

Conditions studied: Osteoporosis

In brief

HORIZON-PFT (Pivotal Fracture Trial) will study the effect of zoledronic acid, given once per year, on the treatment of osteoporosis in women past menopause. Hip and vertebral fractures are the most devastating consequences of osteoporosis. HORIZON-PFT is designed to determine the benefits of zoledronic acid in fracture reduction at both the hip and spine.

Key facts

Study ID
NCT00049829
Run by
Novartis Pharmaceuticals
People needed
7700
Starts
2002-01-01
Last updated by the study team
2011-11-02

Who can join

Age: 65 and older, up to 89. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.